Loading stock data…
$1.71+0.03 (+1.78%)
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers.
TransCode Therapeutics, Inc. in the Healthcare sector is trading at $1.71 with a market capitalization of $2M. The stock is currently near its 52-week low of $1.52, remaining 73.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.21M↑ | -$17.62M↓ | -$6.49M↓ | -$4.54M↓ | -$4.07M |
| Net Income | -$6.75M↑ | -$17.79M↓ | -$13.44M↓ | -$4.86M↓ | -$4.28M |
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of pati...